Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 21 results.
User Information
Export Records
  1. 1.   TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells
  2. Kundu, Manjari; Greer, Yoshimi E; Lobanov, Alexei; Ridnour, Lisa; Donahue, Renee N; Ng, Yeap; Ratnayake, Shashi; White, Karley; Voeller, Donna; Weltz, Sarah; Chen, Qingrong; Lockett,Stephen; Cam, Maggie; Meerzaman, Daoud; Wink, David A; Weigert, Roberto; Lipkowitz, Stanley
  3. Cancer Letters. 2025, Jun 28; 620: 217692.
  1. 2.   IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis
  2. Starkey, Malcolm R; Plank, Maximilian W; Casolari, Paolo; Papi, Alberto; Pavlidis, Stelios; Guo, Yike; Cameron, Guy J M; Haw, Tatt Jhong; Tam, Anthony; Obiedat, Ma'en; Donovan, Chantal; Hansbro, Nicole G; Nguyen, Duc H; Nair, Prema Mono; Kim, Richard Y; Horvat, Jay C; Kaiko, Gerard E; Durum,Scott; Wark, Peter A; Sin, Don D; Caramori, Gaetano; Adcock, Ian M; Foster, Paul S; Hansbro, Philip M
  3. The European respiratory journal. 2019, JUL 1; 54(1): pii: 1800174..
  1. 3.   Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
  2. Lee, S.; Yagita, H.; Sayers, T. J.; Celis, E.
  3. Cancer Immunology Immunotherapy. 2010, Jul; 59(7): 1073-1081.
  1. 4.   Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody
  2. Feng, Y.; Xiao, X. D.; Zhu, Z. Y.; Dimitrov, D. S.
  3. Mabs. 2010, Sep-Oct; 2(5): 565-570.
  1. 5.   Application of tissue-specific NK and NKT cell activity for tumor immunotherapy
  2. Subleski, J. J.; Wiltrout, R. H.; Weiss, J. M.
  3. Journal of Autoimmunity. 2009, Nov-Dec; 33(3-4): 275-281.
  1. 6.   Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
  2. Hallett, W.; Ames, E.; Motarjemi, M.; Barao, I.; Shanker, A.; Tamang, D. L.; Sayers, T. J.; Hudig, D.; Murphy, W. J.
  3. Journal of Immunology. 2008 180(1): 163-170.
  1. 7.   Productively combining proteasome inhibition with the immunotherapy of cancer
  2. Sayers, T.
  3. Journal of Molecular Medicine-jmm. 2008 86(8): 857-860.
  1. 8.   T cell tolerance to tumors and cancer immunotherapy
  2. Shafer-Weaver, K.; Anderson, M.; Malyguine, A.; Hurwitz, A. A.
  3. Immune-Mediated Diseases: From Theory to Therapy. 2007; 601 : 357-368.
  1. 9.   NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function
  2. Abdool, K.; Cretney, E.; Brooks, A. D.; Kelly, J. M.; Swann, J.; Shanker, A.; Bere, E. W.; Yokoyama, W. M.; Ortaldo, J. R.; Smyth, M. J.; Sayers, T. J.
  3. Journal of Immunology. 2006, Aug; 177(4): 2575-2583.
  1. 10.   TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
  2. Cretney, E.; Shanker, A.; Yagita, H.; Smyth, M. J.; Sayers, T. J.
  3. Immunology and Cell Biology. 2006, FEB; 84(1): 87-98.
  1. 11.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 12.   Biology of natural killer cells: What is the relationship between natural killer cells and cancer? Will an increased number and/or function of natural killer cells result in lower cancer incidence?
  2. Anderson, S. K.
  3. Journal of Nutrition. 2005, DEC; 135(12): 2910S-2910S.
  1. 13.   TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells
  2. Herbeuval, J. P.; Boasso, A.; Grivel, J. C.; Hardy, A. W.; Anderson, S. A.; Dolan, M. J.; Chougnet, C.; Lifson, J. D.; Shearer, G. M.
  3. Blood. 2005 105(6): 2458-2464.
  1. 14.   NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer
  2. Smyth, M. J.; Swann, J.; Kelly, J. M.; Cretney, E.; Yokoyama, W. M.; Diefenbach, A.; Sayers, T. J.; Hayakawa, Y.
  3. Journal of Experimental Medicine. 2004, NOV 15; 200(10): 1325-1335.
  1. 15.   Nitric oxide, a mediator of inflammation, suppresses tumorigenesis
  2. Hussain, S. P.; Trivers, G. E.; Hofseth, L. J.; He, P. J.; Shaikh, I.; Mechanic, L. E.; Doja, S.; Jiang, W. D.; Subleski, J.; Shorts, L.; Haines, D.; Laubach, V. E.; Wiltrout, R. H.; Djurickovic, D.; Harris, C. C.
  3. Cancer Research. 2004, OCT 1; 64(19): 6849-6853.
  1. 16.   Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils
  2. Kamohara, H.; Matsuyama, W.; Shimozato, O.; Abe, K.; Galligan, C.; Hashimoto, S. I.; Matsushima, K.; Yoshimura, T.
  3. Immunology. 2004 111(2): 186-194.
  1. 17.   Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy
  2. Takeda, K.; Yamaguchi, N.; Akiba, H.; Kojima, Y.; Hayakawa, Y.; Tanner, J. E.; Sayers, T. J.; Seki, N.; Okumura, K.; Yagita, H.; Smyth, M. J.
  3. Journal of Experimental Medicine. 2004 199(4): 437-448.
  1. 18.   Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques - Evidence that dendritic cells are early and sustained targets of infection
  2. Geisbert, T. W.; Hensley, L. E.; Larsen, T.; Young, H. A.; Reed, D. S.; Geisbert, J. B.; Scott, D. P.; Kagan, E.; Jahrling, P. B.; Davis, K. J.
  3. American Journal of Pathology. 2003 163(6): 2347-2370.
  1. 19.   NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade
  2. Koh, C. Y.; Ortaldo, J. R.; Blazar, B. R.; Bennett, M.; Murphy, W. J.
  3. Blood. 2003 102(12): 4067-4075.
  1. 20.   Antigen-primed CD8(+) T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1- and TRAIL-dependent killing
  2. Komatsu, M.; Mammolenti, M.; Jones, M.; Jurecic, R.; Sayers, T. J.; Levy, R. B.
  3. Blood. 2003 101(10): 3991-3999.
  1. 21.   Regulation of natural killer cell function
  2. Makrigiannis, A. P.; Anderson, S. K.
  3. Cancer Biology & Therapy. 2003, NOV-DEC; 2(6): 610-616.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel